Small molecule inhibitors of the HIV-1 virulence factor, Nef

Publication date: December 2013 Source:Drug Discovery Today: Technologies, Volume 10, Issue 4 Author(s): Thomas E. Smithgall , Gary Thomas Although antiretroviral therapy has revolutionized the clinical management of AIDS, life-long treatment is required because these drugs do not eradicate HIV-infected cells. Chronic antiretroviral therapy may not protect AIDS patients from cognitive impairment, raising important quality of life issues. Because of the rise of HIV strains resistant to current drugs and uncertain vaccine prospects, an urgent need exists for the discovery and development of new therapeutic approaches. This review is focused on one such approach, which involves targeting HIV-1 Nef, a viral accessory protein essential for AIDS pathogenesis.
Source: Drug Discovery Today: Technologies - Category: Drugs & Pharmacology Source Type: research